Wedbush Forecasts AnaptysBio's Q4 Earnings (NASDAQ:ANAB)

Key Points

• Wedbush analysts predict AnaptysBio will report a Q4 2026 earnings per share of ($0.84), maintaining an "Outperform" rating with a price target of $45.00.
• Despite recent negative performance, with shares down 2.6%, the stock holds a consensus rating of "Moderate Buy" and a target of $47.75 among analysts.
• Insider activity includes significant selling, as Director Hollings Renton sold over 20,000 shares, reducing their holdings by approximately 80.82%.

AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Investment analysts at Wedbush issued their Q4 2026 earnings per share estimates for shares of AnaptysBio in a report issued on Thursday, August 7th. Wedbush analyst D. Nierengarten forecasts that the biotechnology company will post earnings per share of ($0.84) for the quarter. Wedbush has a "Outperform" rating and a $45.00 price objective on the stock. The consensus estimate for AnaptysBio's current full-year earnings is ($6.08) per share.

A number of other analysts have also recently weighed in on ANAB. Guggenheim reissued a "buy" rating and issued a $90.00 price objective (up previously from $54.00) on shares of AnaptysBio in a research report on Wednesday, May 28th. HC Wainwright raised AnaptysBio from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $22.00 to $38.00 in a research report on Wednesday, June 4th. Finally, JPMorgan Chase & Co. raised their price objective on AnaptysBio from $42.00 to $80.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $47.75.

AnaptysBio Stock Down 2.6%

Shares of AnaptysBio stock traded down $0.53 during trading on Friday, reaching $19.85. The company's stock had a trading volume of 221,397 shares, compared to its average volume of 774,203. The company has a market cap of $583.05 million, a price-to-earnings ratio of -4.41 and a beta of -0.20. AnaptysBio has a 1-year low of $12.21 and a 1-year high of $41.31. The company has a 50-day simple moving average of $24.22 and a two-hundred day simple moving average of $20.42.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.50) by $0.16. The business had revenue of $22.26 million for the quarter, compared to analysts' expectations of $11.55 million. AnaptysBio had a negative return on equity of 210.18% and a negative net margin of 107.66%.

Insider Buying and Selling

In other AnaptysBio news, Director Hollings Renton sold 20,925 shares of AnaptysBio stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $23.57, for a total transaction of $493,202.25. Following the completion of the sale, the director owned 4,965 shares of the company's stock, valued at approximately $117,025.05. The trade was a 80.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 33.50% of the company's stock.

Hedge Funds Weigh In On AnaptysBio

A number of institutional investors have recently modified their holdings of the stock. Los Angeles Capital Management LLC purchased a new position in shares of AnaptysBio during the 2nd quarter valued at about $334,000. Savant Capital LLC purchased a new position in shares of AnaptysBio during the 2nd quarter valued at about $241,000. Corton Capital Inc. raised its stake in shares of AnaptysBio by 12.2% during the 2nd quarter. Corton Capital Inc. now owns 12,004 shares of the biotechnology company's stock valued at $266,000 after buying an additional 1,305 shares during the last quarter. Bleakley Financial Group LLC purchased a new position in shares of AnaptysBio during the 2nd quarter valued at about $834,000. Finally, Allianz Asset Management GmbH purchased a new position in shares of AnaptysBio during the 2nd quarter valued at about $337,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.